|
Dec 13, 2006 |
Access Pharmaceuticals Receives MuGard™ Marketing Clearance from FDA.
|
|
Dec 11, 2006 |
Access Pharmaceuticals Announces Revised $10 Million Agreement with ULURU, Inc.
|
|
Oct 23, 2006 |
Access Pharmaceuticals To Present At The Rodman & Renshaw 8th Annual Healthcare Conference
|
|
Sep 20, 2006 |
Access Pharmaceuticals Announces the Filing of a 510(k) Application for MuGard™
|
|
Sep 05, 2006 |
Access Pharmaceuticals Announces Board Changes
|
|
Jun 22, 2006 |
Access Pharmaceuticals Announces Clinical Results of MuGard™ at a Major Supportive Care Conference
|
|
Jun 08, 2006 |
Access Pharmaceuticals Announces Dosing of ProLindac™ in First Patient in its Phase II Trial
|
|
Jun 07, 2006 |
Access Pharmaceuticals Provides Update on Strategic Oncology Focus: ProLindac™ and MuGard™
|
|
Jun 05, 2006 |
Access Pharmaceuticals Implements 1 for 5 Reverse Stock Split
|
|
Feb 26, 2006 |
Access Pharmaceuticals Announces the Commencement of a New AP5346 Clinica Study
|
|
Feb 17, 2006 |
Access Pharmaceuticals Completes $5.0 Million Convertible Note Offering
|
|
Jan 31, 2006 |
Access Pharmaceuticals Receives Notice of AMEX Delisting
|